



Consolidated Statements of Operations
(Amounts in thousands, except per share amounts)
(Unaudited)

	April 1, 2022	July 1, 2022	September 30, 2022	December 31, 2022	March 31, 2023	June 30, 2023	September 29, 2023	December 31, 2023
Revenue	\$ 204,216	\$ 215,356	\$ 222,958	\$ 218,373	\$ 219,126	\$ 229,464	\$ 221,503	\$ 211,569
Cost of revenue	113,940	120,111	124,550	123,830	121,498	125,341	119,912	115,014
Gross profit	90,276	95,245	98,408	94,543	97,628	104,123	101,591	96,555
Operating expenses:								
Research and development and engineering	20,929	21,588	21,349	21,904	22,828	23,380	22,022	23,452
Selling, general and administrative	39,352	40,538	40,301	38,710	40,923	42,187	39,648	41,702
Amortization of purchased intangible assets	7,342	7,173	6,472	5,351	5,089	5,124	5,131	5,101
Restructuring, acquisition, and related costs	(1,630)	2,655	1,625	1,734	2,476	1,234	4,481	4,623
Total operating expenses	65,993	71,954	69,747	67,699	71,316	71,925	71,282	74,878
Operating income	24,283	23,291	28,661	26,844	26,312	32,198	30,309	21,677
Interest income (expense), net	(3,109)	(2,757)	(4,062)	(5,688)	(6,332)	(6,810)	(6,756)	(5,920)
Foreign exchange transaction gains (losses), net	69	152	2,086	(2,240)	(77)	74	(370)	118
Other income (expense), net	(545)	68	87	19	(166)	(191)	(189)	(129)
Income before income taxes	20,698	20,754	26,772	18,935	19,737	25,271	22,994	15,746
Income tax provision (benefit)	1,878	3,275	4,282	3,673	1,472	4,392	1,771	3,235
Net income	\$ 18,820	\$ 17,479	\$ 22,490	\$ 15,262	\$ 18,265	\$ 20,879	\$ 21,223	\$ 12,511
Earnings per common share:								
Basic	\$ 0.53	\$ 0.49	\$ 0.63	\$ 0.43	\$ 0.51	\$ 0.58	\$ 0.59	\$ 0.35
Diluted	\$ 0.53	\$ 0.49	\$ 0.63	\$ 0.42	\$ 0.51	\$ 0.58	\$ 0.59	\$ 0.35
Weighted average common shares outstanding—basic	35,538	35,609	35,729	35,738	35,810	35,851	35,856	35,858
Weighted average common shares outstanding—diluted	35,781	35,933	35,928	36,000	35,999	36,032	36,041	36,052
Adjusted EBITDA (Non-GAAP):								
Net Income (GAAP)	\$ 18,820	\$ 17,479	\$ 22,490	\$ 15,262	\$ 18,265	\$ 20,879	\$ 21,223	\$ 12,511
Interest (income) expense, net	3,109	2,757	4,062	5,688	6,332	6,810	6,756	5,920
Income tax provision	1,878	3,275	4,282	3,673	1,472	4,392	1,771	3,235
Depreciation and amortization	14,036	13,811	13,143	12,159	11,731	11,397	11,397	11,547
Share-based compensation	6,774	5,081	5,954	5,299	6,466	5,875	6,037	7,210
Employee COVID-19 testing costs	125	39	-	76	-	-	-	-
Restructuring, acquisition and related costs	(1,630)	2,655	1,625	1,734	2,476	1,234	4,481	4,628
Acquisition fair value adjustments	-	160	-	-	-	-	-	-
Inventory related charges associated with a product line closure	-	-	-	-	-	473	-	-
Write-off unamortized deferred financing costs	624	-	-	-	-	-	-	-
Other, net	(148)	(220)	(2,173)	2,221	243	117	559	252
Adjusted EBITDA (Non-GAAP)	\$ 43,588	\$ 45,037	\$ 49,383	\$ 46,112	\$ 46,985	\$ 51,717	\$ 52,224	\$ 45,303